Prevalence of Flexor Carpi Radialis Brevis in Chinese Patients with Volar Wrist Plating Performed for Distal Radius Fracture.

Background: Volar locking plates were increasing popular as treatment of distal radius fractures. Various distal forearm anatomical variants were encountered during surgery. Flexor carpi radialis brevis (FCRB) was one of the most common and relevant anatomical variants because of its close proximity to fracture site. Methods: This is a retrospective single-centre study. In a 3.5-year period from March 2015 to August 2018, 133 patients who suffered from distal radius fracture requiring volar wrist plating were identified. Operation records and clinical photos were reviewed. All patients were followed up for at least 1 year. Any complications were recorded. Results: 9 patients with FCRB variant were identified. The prevalence was 6.8%. Hypoplastic pronator quadratus were found in 5 cases out of the 9 cases. None of these cases had any neurovascular injuries. No complications were noted during follow-up at 1 year. Conclusions: In Chinese population with volar locking plate done for distal radius fracture, the prevalence of flexor carpi radialis brevis was 6.8%. Surgeons should be aware of the possibility of FCRB variant.

The diagnostic and management challenge for concomitant fragility fractures of pelvis and hip - a Case series with literature review.

BACKGROUND: Fragility fractures of hip and pelvis in the elderly population are common. They do co-exist but are frequently missed and undertreated. METHODS AND RESULTS: 3 cases of concomitant fragility fractures of hip and pelvis were identified. Hip fractures were treated with cemented hemiarthroplasty or cephalomedullary nail fixation, while pelvic fractures were treated with percutaneous screw fixation in same general anesthesia session. Anti-osteoporotic treatments were offered. Subjects were followed up for 1 year. CONCLUSION: Surgical treatment of fragility hip and pelvic fractures improves fracture stability, achieves better pain relief and allows earlier mobilization. Anti-osteoporotic treatment is essential as secondary prevention in fragility fractures.

Pre-operative intravenous steroid improves pain and joint mobility after total knee arthroplasty in Chinese population: a double-blind randomized controlled trial.

INTRODUCTION: This study aims to investigate the effect of pre-operative intravenous methylprednisolone on post-operative pain control and joint mobility in Chinese patients undergoing single primary total knee arthroplasty. METHODS: This is a prospective, randomized, double-blinded, placebo-controlled single-centre trial. Sixty subjects were randomized into intervention and control group. The peri-operative anaesthetic and analgesic regimes were standardized. The intervention group received 125 mg methylprednisolone intravenously on the induction of anaesthesia. Subjects were assessed at 24, 30 and 48 h after surgery and upon discharge for pain scores and range of movement from the operated knee. Change in C-reactive protein level was calculated. Patient's satisfaction was recorded. Adverse reactions were documented. Subjects were followed up at 6 weeks, 4 months and 1 year. RESULTS: Rest pain and pain on movement were significantly reduced in the methylprednisolone group at 24 and 30 h after surgery (ANOVA p = 0.030, p = 0.003, p = 0.032, p = 0.010). The methylprednisolone group demonstrated a greater range of movement from the operated knee up to 30 h after surgery (ANOVA p = 0.031). Post-operative C-reactive protein level was significantly less in the methylprednisolone group (p < 0.001). Methylprednisolone group had a higher patient's satisfaction than the control group (p < 0.01). No adverse effects were noted at the 1-year follow-up. CONCLUSION: Pre-operative intravenous methylprednisolone improves post-operative pain and joint mobility after total knee arthroplasty up to 30 h after operation. It results in a higher patients' satisfaction. It can act as an effective adjunct in the multimodal analgesic regime. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT03082092.